Replies to post #102629 on Anavex Life Sciences Corp (AVXL)

[ExtremelyBullishZig]

I agree that we need to play the devil's advocate, but we cannot be the devil's advocate for 15-month data. Its greatness wasn't an assumption...it was already an approved abstract of stabilizing and increasing cognitive scores for the last conference. It was pulled...but that doesn't change the fact that the abstract was reviewed and approved before hand.

[stockaesthetics]

Let's say PK/PD data is not what the market wants to hear

I'm curious what you think is the optimal PK/PD data that the market wants to hear.

[Whatsupp]

"So the good doctor says to himself: rather than release mediocre Ph2a data or PK/PD analysis (it looked good, but when we turned away and looked again at fifteen months, it looked less good) and watch the share price plummet, why not start the Rett's trial and, when the share price rises on hope, raise money for the Ph2b ALZ trial?"

The problem with your argument is that it makes too much sense. How is anyone going to believe such a rational thought when convoluted theories sound so much better?